Cargando…
Erratum to: Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676102/ https://www.ncbi.nlm.nih.gov/pubmed/36130114 http://dx.doi.org/10.1093/eurheartj/ehac534 |
Ejemplares similares
-
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome:
the dal-GenE trial( )
por: Tardif, Jean Claude, et al.
Publicado: (2022) -
Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib
por: Black, Donald M., et al.
Publicado: (2018) -
Erratum to “Slender Sheath/Guiding Catheter Combination vs. Sheathless Guiding Catheter for Acute Coronary Syndrome: A Propensity-Matched Analysis of the Two Devices”
por: Isawa, Tsuyoshi, et al.
Publicado: (2020) -
Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans
por: Brodeur, Mathieu R., et al.
Publicado: (2022) -
Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease
por: Schwartz, Gregory G., et al.
Publicado: (2020)